Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 20/20 | 0.79 |
| ▸ | DRD3 | P35462 | 19/20 | 0.79 |
| ▸ | DRD2 | P14416 | 15/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL378375 | 1.00 | KCNH2 (0.79) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL11911820 | 1.00 | KCNH2 (0.79) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL378306 | 0.92 | KCNH2 (0.68) | KCNH2DRD3DRD2 | |
| Hydrochloric Acid SCHEMBL378883 | 0.91 | KCNH2 (0.67) | KCNH2DRD3DRD2 | |
| SCHEMBL5243758 | 0.91 | KCNH2 (0.67) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL5244397 | 0.91 | KCNH2 (0.67) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL378506 | 0.91 | KCNH2 (0.67) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL11914551 | 0.91 | KCNH2 (0.67) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL5244390 | 0.91 | KCNH2 (0.67) | KCNH2DRD3DRD2CYP1A2CYP2D6 | |
| SCHEMBL11915309 | 0.89 | KCNH2 (0.80) | KCNH2DRD3DRD2CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HAMPRECHT DIETER (IT) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196910-A1 | USE OF AZABICYCLO HEXANE DERIVATIVES | HTT, GBA2, GBA1 | KCNH2 4867/4885DRD3 1131/4885DRD2 772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.